Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Total Debt (2020 - 2025)

Maravai Lifesciences Holdings (MRVI) has 6 years of Total Debt data on record, last reported at $291.8 million in Q4 2025.

  • For Q4 2025, Total Debt fell 1.41% year-over-year to $291.8 million; the TTM value through Dec 2025 reached $291.8 million, down 1.41%, while the annual FY2025 figure was $291.8 million, 1.41% down from the prior year.
  • Total Debt reached $291.8 million in Q4 2025 per MRVI's latest filing, roughly flat from $292.8 million in the prior quarter.
  • Across five years, Total Debt topped out at $748.3 million in Q4 2021 and bottomed at $288.4 million in Q2 2025.
  • Average Total Debt over 5 years is $516.4 million, with a median of $525.4 million recorded in 2023.
  • Peak YoY movement for Total Debt: surged 39.97% in 2021, then tumbled 44.8% in 2025.
  • A 5-year view of Total Debt shows it stood at $748.3 million in 2021, then decreased by 29.52% to $527.4 million in 2022, then fell by 0.62% to $524.1 million in 2023, then plummeted by 43.54% to $295.9 million in 2024, then decreased by 1.41% to $291.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Debt were $291.8 million in Q4 2025, $292.8 million in Q3 2025, and $288.4 million in Q2 2025.